Media Center

In the media

TechShare, el programa que abre las puertas de la Bolsa a las pymes biotech

Innovaspain

26/09/2018

Cómo facilitar la salida a bolsa de empresas biotecnológicas

Diario Medico

26/09/2018

ABILITY PHARMA COMENÇA LA FASE 2 DEL SEU NOU ANTICANCERIGEN

La Vanguardia

20/09/2018

ABILITYPHARMA ABRE UNA RONDA PARA LUCHAR CONTRA EL CÁNCER

Expansión

13/09/2018

The FDA approves a clinical trial of AbilityPharma

Expansión

20/02/2018

Ability Pharma gets FDA nod for a new clinical trials

Diari de Sabadell

20/02/2018

Ability receives FDA authorization to start clinical trials

Expansión

14/12/2017

Ability Pharma seeks 2.5 million to expand clinical trials

Expansión

09/10/2017

Ability Pharma receives the OK from France for testing a new drug

Diari Sabadell

09/10/2017

ABILITY PHARMA ACHIEVES THE DISTINCTION OF ORPHAN DRUG IN THE EU

Expansión

19/09/2017

REWARD TO MINORYX AND ABILITY AUDACITY

Expansión

15/12/2016

Ability Pharma strengthens in the US

El Periódico

14/12/2016

AbilityPharma starts the Phase 2 with the anticancer drug ABTL0812

Diari de Sabadell

06/12/2016

The phase 2 of the antitumoral drug starts

La Vanguardia

23/11/2016

Start of a clinical trial with a new drug for lung and endometiral cancer

La Vanguardia online

22/11/2016

ABTL0812, from AbilityPharmaceuticals, is designed Orphan

Diaro Médico

08/04/2015

European support to the oncology investigation

La Vanguardia

08/04/2015

Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma

Siege to cancer from Bellaterra

L'Econòmic - El Punt Avui

19/02/2013

The biomedical company Ability Pharmaceuticals obtains financing for a pioneering treatment for pancreatic and lung cancer in humans

Ability Pharma, 1.2 million to enter clinical phase.

La Vanguardia

11/02/2013

Ability Pharma raises 1 million euros for a new drug.

Expansión

07/02/2013

LATEST NEWS

07.11.2018

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018

News

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
19.02.2018

News

AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
13.12.2017

News

AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + info
05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
20.02.2017

News

Ability Pharmaceuticals launches a new updated website with a fresh design + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG